Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center

Purpose New therapeutic approaches for ulcerative colitis (UC) are now available, but there is still no robust evidence for predictors of poor outcomes. We aimed to evaluate the factors associated with a chronic active UC disease course. Patients and Methods Data of all UC outpatients followed for at least 3 years after diagnosis between 2005 and 2018 were retrospectively collected. The primary aim was to identify risk factors for chronic active disease 3 years after diagnosis. Moreover, the following variables were investigated: proximal disease extension or disease regression, proctocolectomy, early use of biologics (BIO) or immunomodulators (IMM), hospitalization, colorectal cancer, and adherence. We defined adherence as both, taking the prescribed therapy and constancy in scheduled follow-up visits. Results A total of 345 UC patients followed for a median period of 82 months were included. Patients with extensive colitis at diagnosis had a higher rate of chronic active disease 3 years after diagnosis (p<0.012) together with a higher rate of surgery (p<0.001) at maximum follow-up. Patients with pancolitis showed significant disease regression over time (51%) without differences in treatment. The only factor associated with chronic active disease was non-adherence (p < 0.03; OR 0.49, 95% CI: 0.26–0.95). Adherent patients developed chronic active disease (p<0.025) less frequently but did receive more frequent IMM (p<0.045) or BIO (p<0.009) therapy. Conclusion Patients diagnosed with pancolitis were more likely to have chronic active disease and to undergo colectomy. The only predictor for developing chronically active UC regardless of disease extension was the lack of adherence to therapy within the first 3 years after diagnosis, underlining the importance of tight control of UC patients and the need to timely identify potential risk factors for non-adherence.

[1]  K. Fushimi,et al.  Depression is associated with increased disease activity in patients with ulcerative colitis: A propensity score‐matched analysis using a nationwide database in Japan , 2022, JGH open : an open access journal of gastroenterology and hepatology.

[2]  J. Burisch,et al.  Psychiatric disorders in adult and paediatric patients with inflammatory bowel diseases - a systematic review and meta-analysis. , 2022, Journal of Crohn's & colitis.

[3]  N. Bhala,et al.  The association between inflammatory bowel disease and mental ill health: a retrospective cohort study using data from UK primary care , 2022, Alimentary pharmacology & therapeutics.

[4]  R. Gearry,et al.  The disease severity index for inflammatory bowel disease is associated with psychological symptoms and quality of life, and predicts a more complicated disease course , 2022, Alimentary pharmacology & therapeutics.

[5]  Liu Yang,et al.  Psychological Factors Associated With Adherence to Oral Treatment in Ulcerative Colitis. , 2022, Inflammatory bowel diseases.

[6]  D. Rubin,et al.  WHAT DOES DISEASE PROGRESSION LOOK LIKE IN ULCERATIVE COLITIS AND HOW MIGHT IT BE PREVENTED? , 2022, Gastroenterology.

[7]  J. Andrews,et al.  Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis , 2021, European journal of gastroenterology & hepatology.

[8]  A. Cohen,et al.  Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[9]  M. Vatn,et al.  Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study , 2020, Journal of Crohn's & colitis.

[10]  M. Vatn,et al.  Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study , 2020, BMJ open gastroenterology.

[11]  H. Sørensen,et al.  Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study , 2020, The Lancet.

[12]  M. Pastore,et al.  Disease activity patterns in the first 5 years after diagnosis in children with ulcerative colitis: a population-based study. , 2019, Journal of Crohn's & colitis.

[13]  J. Feuerstein,et al.  Surgery in the age of biologics , 2019, Gastroenterology report.

[14]  Minhu Chen,et al.  Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study , 2019, BMC Gastroenterology.

[15]  D. Hommes,et al.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial , 2017, The Lancet.

[16]  T. Taft,et al.  Psychological Considerations and Interventions in Inflammatory Bowel Disease Patient Care. , 2017, Gastroenterology clinics of North America.

[17]  G. Colombo,et al.  Adherence in ulcerative colitis: an overview , 2017, Patient preference and adherence.

[18]  J. Halfvarson,et al.  Long‐term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients , 2017, Alimentary pharmacology & therapeutics.

[19]  C. Sofia,et al.  Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era , 2016, European journal of gastroenterology & hepatology.

[20]  S. Ng,et al.  Development of an index to define overall disease severity in IBD , 2016, Gut.

[21]  B. Corfe,et al.  Systematic review: psychological morbidity in young people with inflammatory bowel disease – risk factors and impacts , 2016, Alimentary pharmacology & therapeutics.

[22]  T. Taft,et al.  A systematic review of disease-related stigmatization in patients living with inflammatory bowel disease , 2016, Clinical and experimental gastroenterology.

[23]  P. Higgins,et al.  Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  L. Peyrin-Biroulet,et al.  Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review , 2013, Inflammatory bowel diseases.

[25]  P. Hodgkins,et al.  Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis , 2012, BMC Gastroenterology.

[26]  G. Latella,et al.  Crucial steps in the natural history of inflammatory bowel disease. , 2012, World journal of gastroenterology.

[27]  J. Lindsay,et al.  Factors Associated With Nonadherence to Thiopurines in Adolescent and Adult Patients With Inflammatory Bowel Disease , 2012, Journal of pediatric gastroenterology and nutrition.

[28]  R. Baldassano,et al.  Treatment adherence in adolescents with inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/depressive symptoms. , 2012, Journal of pediatric psychology.

[29]  K. Mazzocco,et al.  Risk factors for non‐adherence to medication in inflammatory bowel disease patients , 2007, Alimentary pharmacology & therapeutics.

[30]  E. Cabré,et al.  Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease , 2006, Digestive Diseases and Sciences.

[31]  M. Vatn,et al.  Ulcerative colitis and clinical course: Results of a 5‐year population‐based follow‐up study (the IBSEN study) , 2006, Inflammatory bowel diseases.

[32]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[33]  H. Leufkens,et al.  5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study , 2005, Gut.

[34]  M. J. Shale,et al.  Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[35]  S. Hanauer,et al.  Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.

[36]  T. Vallis,et al.  Quality of life in inflammatory bowel disease: the interaction of disease activity with psychosocial function. , 1995, The American journal of gastroenterology.

[37]  E. Blanchard,et al.  Long-term monitoring of psychosocial stress and symptomatology in inflammatory bowel disease. , 1994, Behaviour research and therapy.

[38]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[39]  L. Green,et al.  Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.